As per the latest research by DelveInsight, it is expected to see significant expansion over the forecast period (2024-2034).Key players contributing to this growth include Sun Pharmaceutical Industries, Galderma, Eli Lilly, Sanofi, AstraZeneca, Pfizer, and several other major pharmaceutical companies.

DelveInsight Comprehensive Reporting"Severe Atopic Dermatitis Market Insights, Epidemiology and Market Forecast – 2034"It provides a detailed analysis of market trends, historical and projected epidemiology, and treatment developments in the US, EU4 (Germany, France, Italy, Spain), UK, and Japan.

👉 To explore the landscape in detail, click here: Severe Atopic Dermatitis Market Forecast

Key Highlights of the Severe Atopic Dermatitis Market Report:

  • of Severe atopic dermatitis market sizeIt is expected to be valued at approximately USD 10.4 billion in 2023 and grow significantly throughout the forecast period (2024-2034).

  • In January 2025,Corvus Pharmaceuticalsrevealed promising Phase 1 data forSokeritinibIn moderate to severe atopic dermatitis, significant improvements were demonstrated compared to placebo in primary endpoints including IGA 0/1 and EASI-75.

  • In the second half of 2024,Concerto BiosciencePhase I trial of has begunENS-002, Living Biopharmaceutical TargetingStaphylococcus aureus, is an important trigger of severe atopic dermatitis.

  • In October 2024,Eli LillyAnnounces New Phase IIIb Data fromEvglis, there was a marked improvement in adolescents who had not responded adequately.Dupilumab。

  • GaldermaWe will be announcing the latest results fromArcadia and OlympiaPrograms to be evaluatedNemolizumabAt the EADV 2024 conference, we will focus on long-term efficacy and biomarker analysis.

  • Link PharmaceuticalsPositive Phase Ib results to be shared in August 2024 for localized treatmentLNK01004, intended for patients with mild to moderate disease.

  • Within 7MM,USWill hold the largest market share in 2023, followed closely byJapan。

  • Dupixentwas the first biologic agent approved for this condition and continues to lead the market with revenues of approximately US$2 billion in patients with moderate to severe Alzheimer's disease.

  • In 2023, approximately53.3 million diagnosed cases and The number of infected people is 72.4 millionThe prevalence of severe atopic dermatitis was recorded across the 7MM, with a higher proportion of women (29.9 million) than men (23.5 million).

Key Players in the Severe Atopic Dermatitis Market:

Companies shaping the treatment environment for severe atopic dermatitis include:Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharma, Brickell Biotech, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Pfizer, Novartis, RAPT Therapeutics, Allakos, BioMimetix, Connect Biopharma, KeyMed Biosciences, Asana BioSciences and more.

Get a Free Sample of the Severe Atopic Dermatitis Market Report:

https://www.delveinsight.com/report-store/severe-atopic-dermatitis-market

Leading therapies in the severe atopic dermatitis pipeline:

Promising treatments expected to impact the market include:

  • Bermekimab(Janssen Pharmaceuticals)

  • FB825(Oneness Biotech)

  • Lebrikizumab(Eli Lilly)

  • Nemolizumab(Galderma)

  • B244(AO Biome)

  • Ruxolitinib(Insight)

  • Difelikefalin / Corsuba(Cara Therapeutics)

  • From Roflumilast(Arctis Biotherapeutics)

  • Rocatinlimab(Amgen/Kyowa Kirin)

  • Tapinaroff(Dermavant Sciences)

  • Etrasimod(Pfizer/Arena Pharmaceuticals)

  • BMX-010(Biomimetics)

Find out more about upcoming treatments scheduled to capture the market. Severe atopic dermatitis treatment market

Overview of Severe Atopic Dermatitis

Severe atopic dermatitis (AD), commonly referred to as eczema, is a chronic inflammatory skin disease that causes intense itching, redness, and dry patches. It is often associated with asthma and allergic rhinitis and primarily affects children, but may persist into adulthood.

Epidemiology insights

The epidemiology section of the report provides a robust analysis of prevalence, incidence, and demographic patterns across the 7MM from 2020-2034.

Segmentation includes:

  • Total number of people with severe atopic dermatitis

  • Severity-based prevalence

  • Gender distribution

  • Chronic and episodic diagnosis cases

Explore the trend in more detail here. Epidemiological prediction of severe atopic dermatitis

Drug uptake and pipeline development

This section focuses on:

  • Primary treatment initiation schedule

  • Sales trends and treatment uptake patterns

  • Comparative analysis of treatment outcomes

  • Collaborations, acquisitions and licensing activities among major companies

Market Drivers

  • Increasing disease burden and awareness

  • JAK inhibitor approval and adoption

  • Expanding innovative biologics and topical therapies

  • Increasing medical costs

Market Barriers

  • Dependence on OTC medications

  • Delayed diagnosis and inconsistent adherence to treatment

  • Limited guidelines for primary care management

  • Resistance to new treatments

Scope of the report

  • Study period: 2020–2034

  • Geography Covered: US, EU5, Japan

  • Treatment evaluationCurrent and Pipeline Therapies

  • Analysis tools: SWOT, PESTLE, Porter's Five Forces, BCG Matrix

  • Expert Insights: KOL Perspectives, Market Access and Reimbursement Analysis

For more information on companies operating in the severe atopic dermatitis treatment market, please visit @Clinical trials and treatment evaluations for severe atopic dermatitis

table of contents

  1. Overview of the Severe Atopic Dermatitis Market Report
  2. Summary on severe atopic dermatitis
  3. SWOT analysis of severe atopic dermatitis
  4. Overview of the percentage of patients with severe atopic dermatitis
  5. Overview of the severe atopic dermatitis market
  6. Disease background and overview of severe atopic dermatitis
  7. Epidemiology and patient population of severe atopic dermatitis
  8. Number of patients with severe atopic dermatitis by country
  9. Current treatments and medical procedures for severe atopic dermatitis
  10. Unmet Needs in Severe Atopic Dermatitis
  11. New treatment for severe atopic dermatitis
  12. Severe Atopic Dermatitis Market Outlook
  13. Severe Atopic Dermatitis Market Analysis by Country (2020-2034)
  14. Severe Atopic Dermatitis Market Access and Reimbursement
  15. Severe Atopic Dermatitis Market Drivers
  16. Serious Barriers in the Atopic Dermatitis Market
  17. Severe atopic dermatitis in the appendix
  18. How to report severe atopic dermatitis
  19. DelveInsight Features
  20. Disclaimer
  21. About DelveInsight

 

About DelveInsight

DelveInsight is a renowned life sciences research and consulting firm providing robust market intelligence to pharmaceutical and biotechnology companies. The company's services enable stakeholders to make informed decisions through real-world insights and expert strategic consulting to accelerate their business growth.